Investors

Regen Lab is a portfolio medical technology
company focused on the repair, regeneration
and replacement of soft and hard tissue.

Regen Lab is a Swiss medical device company dedicated to advancing autologous regenerative medicine through standardised, reliable and easy-to-use technologies.

Since 2003, Regen Lab has developed and manufactured medical devices designed to support healthcare professionals in the preparation of autologous platelet-rich plasma and related biological preparations. By combining scientific expertise, quality manufacturing and a strong commitment to clinical education, Regen Lab contributes to the responsible development of regenerative medicine across a broad range of medical fields.

Our approach is built on standardisation, reproducibility and compliance, helping healthcare professionals integrate autologous solutions into their practice within a rigorous medical and regulatory framework. Through an international network of partners, clinicians and scientific collaborators, Regen Lab continues to support evidence-based innovation in regenerative medicine worldwide.

Our strategy

Our Marketplace

Regen Lab’s strategy is to strengthen its position as a reference company in autologous regenerative medicine by combining medical device innovation, scientific evidence, clinical education and international development.

Our focus is to provide healthcare professionals with standardised and reliable technologies for the preparation of autologous biological solutions, while supporting responsible clinical practice through training, research and regulatory compliance.

By expanding access to its technologies, developing new scientific collaborations and continuously improving its product platforms, Regen Lab aims to contribute to the advancement of evidence-based regenerative medicine worldwide.

Regen Lab’s strategy is to strengthen its position as a reference company in autologous regenerative medicine by combining medical device innovation, scientific evidence, clinical education and international development.

Our focus is to provide healthcare professionals with standardised and reliable technologies for the preparation of autologous biological solutions, while supporting responsible clinical practice through training, research and regulatory compliance.

By expanding access to its technologies, developing new scientific collaborations and continuously improving its product platforms, Regen Lab aims to contribute to the advancement of evidence-based regenerative medicine worldwide.

Quarterly Results

View all previous quarterly results

Quarterly Results

Financial Planning

Cras ultricies ligula sed magna dictum porta. Praesent sapien massa, convallis a pellentesque nec, egestas non nisi. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere.

Quarterly Results

Financial Planning

Cras ultricies ligula sed magna dictum porta. Praesent sapien massa, convallis a pellentesque nec, egestas non nisi. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere.

Quarterly Results

Financial Planning

Cras ultricies ligula sed magna dictum porta. Praesent sapien massa, convallis a pellentesque nec, egestas non nisi. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere.

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

Q1 2026 Trading Report

We released our Q1 2026 Trading Report on Wednesday 6 May.

You can ask to watch a replay of the webcast for analysts below.

Financial calendar

10 May

Q1 Trading Report

10 May

Q1 Trading Report

10 May

Q1 Trading Report

10 May

Q1 Trading Report

Regen Lab Expert Surgeon Insights Event

We will be hosting an expert surgeon insights event for investors and financial analysts. 

Date: 9 June 2026
Time: 8.30am – 12.45pm

Reports + Presentations

View the previous reports and presentations

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

Quarterly Results

Regen Lab First Quarter 2026

News and Announcements

Votre titre va ici

Explore

Votre titre va ici

Explore

Votre titre va ici

Explore

Votre titre va ici

Explore

Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufa​cturing of high-quality medical devices, intended for cells therapies.

CONTACT US

Discover innovative regenerative medicine solutions with Regen Lab – contact us today to elevate your treatments and enhance patient care!

Copyright © 2026 All rights reserved.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.